Ubi Pharma Inc is a Taiwan-based company mainly engaged in development and manufacturing of protein drugs and special dosage-form drugs. The Company is engaged in research and development, manufacturing and sales of protein drugs and special dosage-form drugs, contract manufacturing of pharmaceuticals, and provision of contract research services.

Employees

Sector

Pharmaceuticals

More about the company

End-of-day quote Taipei Exchange 06/05/2024			5-day change	1st Jan Change
14.25 ^TWD	+1.79%		-.--%	-

08-13	UBI Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
04-27	UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	1.68B 52.81M 46.55M 44.06M 39.76M 75.05M 5.06B 76.08M 528M 203M 2.59B 198M 194M 8.31B	P/E 2024	-9.63x	P/E 2025	-5.68x
Enterprise Value	1.97B 61.87M 54.54M 51.62M 46.58M 87.93M 5.93B 89.14M 618M 238M 3.03B 232M 227M 9.74B	EV / Sales 2024	3.58x	EV / Sales 2025	3.83x
Free-Float	27.79%	Yield 2024 *	-	Yield 2025	-

08-13	UBI Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
04-27	UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12/08/25	UBI Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
30/04/25	UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
13/08/24	UBI Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2024	CI
18/04/24	UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
11/08/23	UBI Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	CI
21/04/23	UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
15/08/22	UBI Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	CI
29/04/22	UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	CI
29/04/22	UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	CI
16/08/21	Medigen Vaccine Biologics : Taiwan rejects COVID vaccine candidate, president to get domestic shot	RE
16/08/21	Medigen Vaccine Biologics : Taiwan denies approval for UBI's COVID-19 vaccine candidate	RE

3 years	10	38.5
5 years	10	103.94
10 years	8.34	288.72

UBI Pharma Inc. Share Price

Stocks

6562

TW0006562002

Pharmaceuticals

Valuation: UBI Pharma Inc.

Latest news: UBI Pharma Inc.

Quotes and Performance

Price Extremes

Managers and Directors: UBI Pharma Inc.

Other Pharmaceuticals

Financials

Company Profile

Manager	Title	Age	Since
Jung Kuang Yang CEO	Chief Executive Officer	-	-
Meng Han Hsu DFI	Director of Finance/CFO	-	10/04/2016
Ying Yun Fan ADM	Chief Administrative Officer	-	28/02/2015

Director	Title	Age	Since
Ying Yun Fan BRD	Director/Board Member	-	29/06/2020
Yan Ning Kuo BRD	Director/Board Member	-	29/06/2020
Yao Hui Wei BRD	Director/Board Member	-	29/06/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
UBI PHARMA INC.	+1.79%	-.--%	-.--%	-55.40%	52.82M
ELI LILLY AND COMPANY	-2.33%	-1.12%	+59.27%	+115.42%	1,056B
JOHNSON & JOHNSON	-1.06%	-1.65%	+45.77%	+69.98%	645B
ABBVIE INC.	-0.65%	-1.36%	+17.22%	+75.49%	465B
MERCK & CO., INC.	-2.66%	-3.71%	+84.92%	+41.15%	368B
ROCHE HOLDING AG	-0.06%	-4.12%	+36.31%	+39.39%	335B
NOVARTIS AG	-0.79%	+3.01%	+21.11%	+27.79%	275B
ASTRAZENECA PLC	-1.19%	-3.09%	+10.75%	+10.61%	255B
AMGEN INC.	-0.50%	+2.75%	+53.85%	+56.84%	229B
GILEAD SCIENCES, INC.	-1.47%	-2.37%	+32.35%	+98.89%	188B
Average	-0.35%	+0.55%	+36.15%	+48.02%	381.58B
Weighted average by Cap.	-0.33%	+0.30%	+44.68%	+71.38%

	2024	2025
Net sales	539M 16.91M 14.9M 14.1M 12.73M 24.03M 1.62B 24.35M 169M 64.96M 828M 63.47M 62.1M 2.66B	514M 16.14M 14.23M 13.47M 12.15M 22.94M 1.55B 23.25M 161M 62.01M 791M 60.6M 59.29M 2.54B
Net income	-175M -5.48M -4.83M -4.57M -4.12M -7.78M -525M -7.89M -54.72M -21.04M -268M -20.56M -20.11M -862M	-296M -9.3M -8.19M -7.76M -7M -13.21M -891M -13.39M -92.89M -35.72M -455M -34.9M -34.15M -1.46B
Net Debt	246M 7.73M 6.81M 6.45M 5.82M 10.98M 741M 11.13M 77.24M 29.7M 379M 29.02M 28.39M 1.22B	289M 9.06M 7.99M 7.56M 6.82M 12.88M 869M 13.06M 90.58M 34.83M 444M 34.03M 33.29M 1.43B